| INTRODUCTION
Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous group of tumors that originate from the diffuse neuroendocrine cell system of the gastrointestinal tract and pancreas. 1 Even though GEP-NET have classically been considered rare neoplasia, recent data have suggested an exponential increase in the incidence of GEP-NET over the last several decades. [2] [3] [4] [5] Specifically, the annual age-adjusted incidence of GEP-NET was 1.09
per 100 000 persons in 1973 compared with 6.98 per 100 000
persons in 2012-a sixfold increase. 4 The prevalence of GEP-NET is now higher than all other gastrointestinal cancers except for colorectal neoplasia. 3 GEP-NET tumors can present with a wide range of histologic features and clinical presentations, as well as variable biological behavior. Depending on the primary site and grade, GEP-NET can have an indolent or aggressive course that can be resistant to many types of treatment. 6 For patients with locoregional disease, curative-intent surgical management of the primary tumor is first-line treatment. In contrast, for patients with more advanced metastatic disease, the goals of resection may include both symptom control, debulking to limit tumor progression, as well as attempts at complete surgical extirpation. 7 While data on overall survival has more commonly been reported, the risk of recurrence following curative resection of primary NET has been less defined. Specifically, data on recurrence after resection, including incidence of recurrence, recurrence pattern and prognostic factors associated with recurrence, remain relatively scarce. 4, [8] [9] [10] [11] Data on recurrence is, however, important to inform patients about the likelihood of treatment success and the risk of recurrence following surgical intervention. In particular, accurate individual patient-based estimates of risk of recurrence may not only assist with patient counseling and inform decision-making, but also help guide follow-up. While nomograms have been reported as useful tools to discriminate the prognosis of patients for a number of different cancers, nomograms have not been widely applied to patients with GEP-NET. 12 Therefore, the objective of the current study was to identify factors associated with recurrence among patients who underwent curative intent resection of GEP-NET using a large multi-institutional database. Using these factors, we sought to develop and validate a nomogram to predict individual patientspecific risk of recurrence after curative-intent surgical resection of non-metastatic primary GEP-NET. 
| Statistical analysis
Discrete variables were described as medians with interquartile range (IQR) and categorical variables were recorded as totals and frequencies. Imputation for missing data were performed using fully conditional specification (FCS) implemented by the multivariate imputation by chained equations (MICE) algorithm. 13 Univariable comparisons were assessed using the chi-squared test or fisher's exact test as appropriate. The outcome for survival analyses was diseasefree survival (DFS), defined as the time interval between the date of surgery and the date of recurrence. Time was censored at the date of the last follow-up assessment for patients without recurrence. Survival curves were estimated using the Kaplan-Meier method and differences between the curves were compared using the log-rank test.
Variables that had a P-value <0.1 on univariate analyses were included in the final multivariable model.
A pseudo-randomization based on the day of birth was used to identify a training set (patients born within the first Most patients were ASA class 2 (n = 568, 41.3%) or 3 (n = 714, 52%), while a smaller subset were class 1 (n = 65, 4.7%) or 4 (n = 27, 2%).
While GEP-NET was not associated with a genetic syndrome in the overwhelming majority of patients (n = 1358, 91.9%), 72 (5%) and 11 (0.8%) patients were diagnosed with Multiple Endocrine Neoplasia type 1 (MEN 1) and Von Hippel-Lindau (VHL) syndromes, respectively.
Overall, 880 (60.4%) patients had a functional GEP-NET. The primary tumor site was pancreas in over one-half of cases (n = 948, 64.2%), followed by jejunum-ileum (n = 198, 13.4%) or duodenum (n = 101, 6.8%). Other sites such as the stomach, appendix, rectum, colon, ampulla, liver, and gallbladder were less common (n = 230, 15.6%). 
| Factors associated with disease-free survival
The analytic cohort was divided into a training set (n = 754, 51.1%) used to identify factors associated with DFS to develop the nomogram;
subsequently, 723 (48.9%) patients were included in the test set to validate the nomogram. The baseline characteristics of patients included in the training and test sets are reported in Table 1 . Of note, there were no differences in the clinico-pathologic variables in the training versus test cohorts.
In assessing the 754 patients in the training cohort, several factors were associated with DFS on univariable analysis ( patients with >3 metastatic lymph nodes (P < 0.001). On multivariable analysis, Ki-67, tumor size, nodal status, and invasion of adjacent organs remained independent predictors associated with DFS (Table 3) . 
| Prediction ability of the nomogram and external validation
The nomogram demonstrated a good ability to predict risk of Among the 207 (14%) patients who relapsed, 63 (31.0%) patients had local recurrence, while 140 (69.0%) patients had a distant recurrence. Of note, the nomogram groupings were also associated with the pattern of recurrence. Specifically, patients in group 1 (n = 37, 46.8%) and group 2 (n = 17, 23.6%) were more likely to recur locally compared with patients in group 3 (n = 7, 16.3%) and group 4 (n = 2, 22.2%) (P = 0.0001)( Figure 3B ). In contrast, the incidence of distant recurrence was only 11.9% (n = 5) among patients in group 1 (PRisk <20%) versus 60.0% among patients in group 4 (PRisk >80%) (P = 0.008; Figure 3C ).
| DISCUSSION
Current recommendations for peri-operative management (ie, analogues of somatostatin, neo-adjuvant, and adjuvant chemotherapy) and post-operative surveillance of patients who undergo . 20 In 2010, the World Health Organization (WHO) described the mitotic count and Ki-67 index as important parameters to effectively grade GEP-NET and included these two parameters in the WHO staging system. 21 Subsequently, the European Neuroendocrine Tumor Society (ENETS) combined the TNM classification with a grading system based on both mitotic count and Ki-67 index. 15, 22, 23 Even though the ENETS staging system has demonstrated to be superior to the AJCC TNM classification, several other clinico-pathologic characteristics have been proposed as additional variables impacting the prognosis of GEP-NET patients, including gender, age at diagnosis, site of primary tumor, grade of differentiation, and site of metastatic disease. [24] [25] [26] There is also no consensus on the optimal cut-off value for Ki-67 index that should be used to stratify patients' prognosis. 27, 28 Furthermore, these staging systems have exclusively focused on stratifying patients with regards to overall survival, rather than risk of recurrence. The aim of our study was to develop and validate a nomogram to accurately predict individual risk of recurrence after curative resection of GEP-NET. Nomograms can be more accurate and clinically applicable tools to predict outcomes in the context of cancer than conventional staging systems. 12 Even though several previous nomograms have been proposed to predict prognosis, risk of lymph 
FIGURE 1
Nomogram predicting the risk of recurrence at 3-, 5-, and 10-year after surgery FIGURE 2 Kaplan Meier curves for disease-free survival stratified on the base of the risk of recurrence predicted by our nomogram (PRisk): group 1 (PRisk <20%), group 2 (PRisk 20-40%), group 3 (PRisk 40-80%), and group 4 (PRisk >80%) node metastasis, distant metastasis, and overall survival after resection of primary GEP-NET, to the best of our knowledge, no nomograms or staging system predicting the risk of recurrence, independently of the anatomical site of primary GEP-NET, have been proposed. 11, [29] [30] [31] [32] [33] [34] [35] Particularly, the impact of the organ site of primary GEP-NET on patients prognosis has not been completely clarified. 36 In the current analysis, site of primary GEP-NET was not associated with the risk of recurrence and the predictive ability of the nomogram was no different among subgroups of patients categorized by different embryological origins of primary GEP-NET (foregut, midgut, and hindgut). The current nomogram is important, therefore, as we developed and validated it using a large multi-institutional international database, including only patients with primary, non-metastatic, GEP-NET.
Four variables (ie, Ki-67 index as a continue variable, node status, tumor size, and invasion of adjacent organs) were strongly associated with risk of recurrence on multivariable analysis and were included in the proposed nomogram. Ki-67 index has been identified as an important biological variable for patients with GEP-NET. 11 In addition, data from other studies have correlated tumor size with the risk of lymph node metastasis. [43] [44] [45] To this point, Sohn et al reported that tumor grade combined with tumor size is an important predictive factor for lymph node metastasis and could serve as a prognostic factor for survival outcomes. 46 Collectively, the data strongly suggest that tumor size impacts prognosis of patients with GEP-NET tumors.
Even though lymph node status has been reported as an important predictor of survival among patients with GEP-NET, there are less data on the impact of metastatic nodal disease on the risk of recurrence.
Analyzing clinico-pathologic factors associated with recurrence in 188 patients who underwent surgery for GEP-NET, Slatger et al reported that lymph node involvement was an important independent risk factor for recurrence (HR 2.61; 95%CI, 1.17-5.83). 39 In a separate study, Dieckhoff et al reported that lymph node ratio (LNR) was a more precise method to predict outcome rather than simple lymph node status. 47 In this analysis, patients with a LNR >0.2 had a 5-year DFS of 46% versus 76% for patients with a LNR ≤0.2. Moreover, only 10% of patients with local disease had recurrence compared with 31% of patients with GEP-NET that invaded adjacent organs or had lymph node metastasis. 50 In a separate study, Strosberg et al reported that the incidence of recurrence peaked approximately 2 years after surgery. 51 In the current study, the proposed nomogram demonstrated good ability to predict 3-, 5-, and 10-year recurrence in both the training and test set. In addition, the nomogram groupings were associated with timing and patterns of recurrence. For example, patients in nomogram groups 1 and 2 were more likely to experience recurrence >36 months from surgery. In contrast, patients in nomogram groups 3 and 4 had a much higher high incidence of recurrence <18 months from surgery, with recurrence >36 months from surgery being less common. In addition to time of recurrence, the nomogram groupings were associated with the pattern of recurrence.
Specifically, while the majority of patients in nomogram group 1 had a similar incidence of local (47%) versus distal recurrence (53%), patients in nomogram groups 3 and 4 were much more likely to experience a distant recurrence rather than a local recurrence. These data strongly suggest that a nomogram based on biological (Ki67, nodal status), as well as anatomical (tumor size, invasion of adjacent organs) factors can help identify which individual patients are at highest risk of recurrence.
Several limitations should be considered when interpreting the results. Given the retrospective design and the multicenter nature of the study, selection bias was possible. While a pseudo-randomization was used to create two cohorts of patients for the development and validation of the nomogram, the nomogram will require further external validation in a separate cohort of patients. In addition, the study cohort included only patients who underwent surgery at one of eight specific academic centers in the United States. Therefore, the results from the current study may not be generalizable to nonacademic, community centers, or lower volume centers. 
